MorphoSys (ETR:MOR) has been given a €42.00 ($49.41) price target by stock analysts at The Goldman Sachs Group in a report released on Monday, Borsen Zeitung reports. The Goldman Sachs Group’s price target indicates a potential upside of 1.40% from the stock’s current price.
MOR has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft set a €46.00 ($54.12) price target on MorphoSys in a research report on Friday, August 6th. JPMorgan Chase & Co. set a €54.00 ($63.53) target price on MorphoSys in a research report on Wednesday, August 4th. Barclays set a €47.00 ($55.29) price target on shares of MorphoSys in a research report on Thursday, September 2nd. Berenberg Bank set a €124.00 ($145.88) price objective on shares of MorphoSys in a report on Thursday, July 29th. Finally, Stifel Nicolaus set a €97.00 ($114.12) target price on shares of MorphoSys in a research note on Monday, July 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of €80.11 ($94.25).
MorphoSys stock opened at €41.42 ($48.73) on Monday. The company has a current ratio of 6.14, a quick ratio of 5.88 and a debt-to-equity ratio of 53.53. MorphoSys has a 1-year low of €43.21 ($50.84) and a 1-year high of €117.90 ($138.71). The firm’s fifty day simple moving average is €50.28 and its 200-day simple moving average is €64.93. The company has a market capitalization of $1.41 billion and a P/E ratio of -13.37.
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.
Featured Story: Why is momentum important to successful trading?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.